Уноси · Publikacije Univerziteta u Banjoj Luci

Significance of ER, PR and HER2 receptor for the occurrence of metastases in breast cancer. Whether certain subtypes frequently metastasized to the lungs (Prediktivni značaj ER, PR i HER2 receptora za pojavu metastaza karcinoma dojke, da li pojedini podtipovi češće metastaziraju u pluća?) (2014)

M. Vještica, Z. Gojković, I. Rakita, S. Jungić, A. Guzijan, J. Jovanić, R. Rašeta, S. Lekić, J. Rožić, Significance of ER, PR and HER2 receptor for the occurrence of metastases in breast cancer. Whether certain subtypes frequently metastasized to the lungs (Prediktivni značaj ER, PR i HER2 receptora za pojavu metastaza karcinoma dojke, da li pojedini podtipovi češće metastaziraju u pluća?), Respiratio vol 4, br 1-2, pp. 52 - 55, 2014

Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action - CA16225 (2018-04)

I. Andreadou, P. Adamovski, M. Bartekova, C. Beauloye, L. Bertrand, D. Biedermann, V. Borutaite, H. Erik Botker, M. Dambrova, S. Chlopicki, Y. Devaux, S. Davidson, F. Di Lisa, D. Djuric, D. Erlinge, I. Falcao-Pires, E. Galatou, D. Garcia-Dorado, A. Garcia-Sosa, H. Girao, M. Gyongyosi, Z. Giricz, D. Healy, G. Heusch, V. Jakovljevic, J. Jovanic, F. Kolar, B. Kwak, P. Leszek, E. Liepnish, S. Longnus, J. Marinovic, D. Muntean, L. Nežić, M. Ovize, P. Paglliaro, C. Pedrosa da Costa Gomes, J. Pernow, A. Persidis, S. Pischke, B. Podesser, F. Prunier, T. Ravingerova, M. Ruiz-Meana, R. Schulz, A. Scridon, K. Slagsvold, J. Lonborg, B. Turan, N. van Royen, M. Vendelin, S. Walsh, D. Yellon, N. Zidar, C. Zuurbier, P. Ferdinandy, D. Hausenloy, Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action - CA16225, Conditioning medicine, Vol. 1, No. 3, pp. 116 - 123, Apr, 2018

Patients perspectives on drug shortages in six European hospital settings – a cross sectional study (2021)

Kuruc Poje D, Kifer D, Huys I, Miranda J, Jenzer H, Miljković N, Hoppe- Tichy T, Bochniarz M, Frotini R, Schwartz D, Vujić- Aleksić V, Nezic L, Rinaki E, Tzimis L, Green K, Jovanic J, Caric B, Mandic D, Vilic K, Bochenek T, Baciv Vrca V, Marusic S, Patients perspectives on drug shortages in six European hospital settings – a cross sectional study, BMC HEALTH SERVICES RESEARCH, pp. 1 - 10, 2021

The effect of myoinositol and metformin on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled trial (2021-06)

V. Soldat-Stanković, S. Popović-Pejičić, S. Stanković, J. Jovanić, J. Bjekić-Macut, S. Livadas, S. Ognjanović, G. Mastorakos, D. Micić, Đ. Macut, The effect of myoinositol and metformin on cardiovascular risk factors in women with polycystic ovary syndrome: a randomized controlled trial, ACTA ENDOCRINOLOGICA-BUCHAREST, Vol. 17, No. 2, pp. 241 - 247, Jun, 2021

Patients perspectives on drug shortages in six European hospital settings – a cross sectional study (2021-07)

D. Kuruc Poje, D. Kifer, I. Huys, J. Miranda, H. Jenzer, N. Miljković, T. Hoppe-Tichy, M. Bochniarz, R. Frontini, D. Schwartz, V. Vujić-Aleksić, L. Nežić, E. Rinaki, L. Tzimis, T. Green, J. Jovanić, B. Carić, D. Mandić, K. Vilić, T. Bochenek, V. Bačić Vrca, S. Marušić, Patients perspectives on drug shortages in six European hospital settings – a cross sectional study, BMC HEALTH SERVICES RESEARCH, Vol. 21, No. 689, Jul, 2021

Klinička prezentacija Marfanov sindrom – prikaz slučaja. (2012)

J. Jovanić, T. Kovačević-Preradović, V. Katić, B. Goronja, N. Dobrijević, L. Kos, D. Smiljanić, M. Šobot, S. Srdić, Klinička prezentacija Marfanov sindrom – prikaz slučaja., Zbornik radova i sažetaka III Kongresa kardiologa Republike Srpske sa međunarodnim učešćem 2012;68., 2012

Karcinom želuca i celijakija – prikaz slučaja (2020)

A. Figurek, M. Vještica, Z. Gojković, J. Jovanić, S. Jungić, P. Dašić, Karcinom želuca i celijakija – prikaz slučaja, Zbornik apstrakata, godina 4. broj 1, 2020

Science Communications Manager, EU-Cardioprotection COST Action Ca-16225 (2017-10)

J. Jovanić, Science Communications Manager, EU-Cardioprotection COST Action Ca-16225, Oct, 2017

Science Communications Manager, EU COST Innovators grant (CIG), Improving Preclinical Assessment of Cardioprotective therapies-IG 16225 network (2022-10)

J. Jovanić, Science Communications Manager, EU COST Innovators grant (CIG), Improving Preclinical Assessment of Cardioprotective therapies-IG 16225 network, Oct, 2022

COST Action Management Committee-European network to tackle Metabolic alterations in heart failure (EU-METAHEART) (2023-10)

J. Jovanić, COST Action Management Committee-European network to tackle Metabolic alterations in heart failure (EU-METAHEART), Oct, 2023

COST Action CA 21153-Network for implementing multiomics approaches in atherosclerotic cardiovascular disease prevention and research (AtheroNET)- Member of working group 1. and 2. WG1-Pathophysiological mechanisms in atherosclerosis WG 2- Personalized models for clinical applications in ASCVD (2023-10)

J. Jovanić, COST Action CA 21153-Network for implementing multiomics approaches in atherosclerotic cardiovascular disease prevention and research (AtheroNET)- Member of working group 1. and 2. WG1-Pathophysiological mechanisms in atherosclerosis WG 2- Personalized models for clinical applications in ASCVD, Oct, 2023

Uticaj prethodnog bronhološkog oboljenja na dužinu preživljavanja žena sa karcinomom pluća o bronha (2011-11)

J. Jovanić, Uticaj prethodnog bronhološkog oboljenja na dužinu preživljavanja žena sa karcinomom pluća o bronha, Nov, 2011

Contrast induced nephropathy- case report (2012-05)

J. Jovanić, Contrast induced nephropathy- case report, May, 2012

Karakteristike karcinoma pluća kod žena u Republici Srpskoj (2012-05)

J. Jovanić, Karakteristike karcinoma pluća kod žena u Republici Srpskoj, May, 2012

Klinička prezentacija Marfanov sindrom-prikaz slučaja (2012-06)

J. Jovanić, Klinička prezentacija Marfanov sindrom-prikaz slučaja, Jun, 2012

Prevention and intervention in cardiology (2017-10)

J. Jovanić, Prevention and intervention in cardiology, Oct, 2017

Unosi